Comparative Pharmacology
Head-to-head clinical analysis: BELDIN versus CETIRIZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELDIN versus CETIRIZINE.
BELDIN vs Cetirizine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine-mediated allergic and inflammatory responses.
Cetirizine is a selective second-generation H1-receptor antagonist that inhibits histamine release from mast cells and basophils, thereby reducing allergic symptoms.
1 capsule (200 mg) orally every 12 hours.
10 mg orally once daily; 5 mg orally once daily for mild symptoms
None Documented
None Documented
Terminal half-life: 8-12 hours (average 10 hours); prolonged in hepatic impairment (up to 24 h) and severe renal impairment (up to 18 h).
Clinical Note
moderateCetirizine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Cetirizine is combined with Fluticasone propionate."
Clinical Note
moderateLevocetirizine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Cyclosporine
Terminal elimination half-life is approximately 8.3 hours in healthy adults; extended to 20 hours in elderly and patients with renal impairment
Renal: 30-50% unchanged; hepatic metabolism: 50-70% (CYP3A4); biliary/fecal: 10-20%.
Primarily renal (60% unchanged in urine); minor biliary/fecal (10%)
Category C
Category A/B
Antihistamine
Antihistamine
"The metabolism of Cyclosporine can be decreased when combined with Levocetirizine."